Daniel J. Renouf

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Eileen M. O’Reilly, Do‐Youn Oh, Neesha C. Dhani et al. · JAMA Oncology · 2019 · 765 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell– and patient-derived tumor organoids

Ling Huang, Audrey Holtzinger, Ishaan Jagan et al. · Nature Medicine · 2015 · 749 citations · Full text

Medicine, Cell Biology, Oncology +16

Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution

Michelle Chan‐Seng‐Yue, Jaeseung Kim, Gavin W. Wilson et al. · Nature Genetics · 2020 · 689 citations · Full text

Medicine, Molecular Biology, Oncology +17

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Lawrence Fong, Andrew Hotson, John D. Powderly et al. · Cancer Discovery · 2019 · 339 citations · Full text

Medicine, Immunology, Oncology +17

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Florence Castan, Anthony Lopez et al. · JAMA Oncology · 2022 · 324 citations · Full text

Medicine, Oncology, Surgery +14